Company news
Cytokinetics, Incorporated (NASDAQ:CYTK) news
Every Cytokinetics, Incorporated press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
August 20, 2026
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive...
July 30, 2026
Cytokinetics to Announce Second Quarter Results on August 6, 2026
July 23, 2026
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
July 7, 2026
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
June 8, 2026
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
June 1, 2026
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026
May 11, 2026
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Sh...
May 8, 2026
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock
May 6, 2026
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obs...
May 5, 2026
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructiv...
May 4, 2026
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
April 28, 2026
Cytokinetics to Announce First Quarter Results on May 5, 2026
April 21, 2026
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
March 16, 2026
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
February 24, 2026
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hype...
February 17, 2026
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
February 12, 2026
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
February 9, 2026
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertroph...
January 27, 2026
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Ca...
January 27, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 20, 2026
CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)
January 12, 2026
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiom...
December 19, 2025
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
December 17, 2025
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 16, 2025
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
December 12, 2025
Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
November 17, 2025
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American ...
November 10, 2025
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
Cytokinetics to Participate in November Investor Conferences
November 4, 2025
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart A...
October 31, 2025
Cytokinetics to Announce Third Quarter Results on November 5, 2025
October 22, 2025
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
September 29, 2025
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
September 24, 2025
Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 23, 2025
Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025
September 18, 2025
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes
September 16, 2025
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
September 16, 2025
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
August 31, 2025
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The ...
August 30, 2025
Cytokinetics to Participate in September Investor Conferences
August 27, 2025
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
August 25, 2025
Cytokinetics Names Jim Daly to Board of Directors
August 20, 2025
Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Cytokinetics to Announce Second Quarter Results On August 7, 2025
July 24, 2025
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
June 10, 2025
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
May 29, 2025